Local and neck recurrences of squamous cell carcinoma of the head and neck
(SCCHN) can mostly be defected early when the patient has regular follow-up
s. Distant metastases though usually remain undiscovered until they produce
clinical symptoms. Since Cyfra 21-1 correlates with the tumor size and sta
ge in SCCHN, we looked for possible connections between Cyfra 21-1 increase
s and the development of distant metastases. The sera of 830 patients with
SCCHN were tested for Cyfra 21-1. The levels were compared with the clinica
l run of the patients. When Cyfra 21-1 levels rose above the threshold of 3
.3 ng/ml (71 out of 830) staging procedures were performed. Tumor growth wa
s found in 50 out of 71 patients with elevated Cyfra levels (70.4%). Cyfra
serum levels in those cases either represented development of distant metas
tases (27 out of 71), or local and neck recurrences. The results of this st
udy show that Cyfra 21-1 is a suitable and helpful serological parameter fo
r the follow-up of patients with SCCHN. In the event of an elevation of Cyf
ra 21-1 above the threshold during follow-np, we would recommend the perfor
mance of a thoracal CT-scan and abdominal omi ultrasound as staging procedu
res.